Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31
Danielle A. Simmons, Brian D. Mills, Robert R. Butler, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 2, pp. 1039-1063
Open Access | Times Cited: 23

Showing 23 citing articles:

Neuroinflammation in Huntington’s Disease: A Starring Role for Astrocyte and Microglia
Julieta Saba, Federico López Couselo, Julieta Bruno, et al.
Current Neuropharmacology (2021) Vol. 20, Iss. 6, pp. 1116-1143
Open Access | Times Cited: 58
The Molecular Pathway of p75 Neurotrophin Receptor (p75NTR) in Parkinson’s Disease: The Way of New Inroads
Naif H. Ali, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Molecular Neurobiology (2023) Vol. 61, Iss. 5, pp. 2469-2480
Closed Access | Times Cited: 26
In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target
Subash C. Malik, Elif G. Sözmen, Bernat Baeza-Raja, et al.
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 9, pp. 772-788
Open Access | Times Cited: 42
An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development
Shubham Upadhayay, Narhari Gangaram Yedke, Vikrant Rahi, et al.
Neurochemical Research (2023) Vol. 48, Iss. 6, pp. 1631-1647
Closed Access | Times Cited: 18
Biomarkers: Role and Scope in Neurological Disorders
Vivek Sharma, Thakur Gurjeet Singh, Vineet Mehta, et al.
Neurochemical Research (2023) Vol. 48, Iss. 7, pp. 2029-2058
Closed Access | Times Cited: 17
Inflammation and Huntington’s disease- a neglected therapeutic target?
Sophie E. Field, Annabel J. Curle, Roger A. Barker
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 5, pp. 451-467
Open Access | Times Cited: 5
Protein glycosylation in urine as a biomarker of diseases
Mingming Xu, Arthur L. B. Yang, Jun Xia, et al.
Translational research (2022) Vol. 253, pp. 95-107
Closed Access | Times Cited: 21
A Novel Huntington’s Disease Assessment Platform to Support Future Drug Discovery and Development
Jingyun Wu, Luisa Möhle, Thomas Brüning, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14763-14763
Open Access | Times Cited: 18
The p75 neurotrophin receptor inhibitor, LM11A-31, ameliorates acute stroke injury and modulates astrocytic proNGF
Sanaz Nasoohi, Pargol Tayefeh Ghahremani, Parsa Alehossein, et al.
Experimental Neurology (2022) Vol. 359, pp. 114161-114161
Open Access | Times Cited: 13
Urinary p75ECD levels in patients with amyotrophic lateral sclerosis: a meta-analysis
Guanzhong Shi, Shuai Shao, Jinxia Zhou, et al.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2021) Vol. 23, Iss. 5-6, pp. 438-445
Closed Access | Times Cited: 12
Current Diagnostic Methods and Non-Coding RNAs as Possible Biomarkers in Huntington’s Disease
Miguel Pellegrini, Guendalina Bergonzoni, Federica Perrone, et al.
Genes (2022) Vol. 13, Iss. 11, pp. 2017-2017
Open Access | Times Cited: 8
LM11A-31, a modulator of p75 neurotrophin receptor, suppresses HIV-1 replication and inflammatory response in macrophages
Golnoush Mirzahosseini, Namita Sinha, Lina Zhou, et al.
Experimental Biology and Medicine (2024) Vol. 249
Open Access | Times Cited: 1
Magnetic Resonance Imaging to Detect Structural Brain Changes in Huntington’s Disease: A Review of Data from Mouse Models
Jenna Hanrahan, Drew P. Locke, Lindsay S. Cahill
Journal of Huntington s Disease (2024) Vol. 13, Iss. 3, pp. 279-299
Open Access | Times Cited: 1
Huntington’s Disease, Cognition, and Biological Markers
Tamara Fernández‐Valle, Ane Murueta‐Goyena
Springer eBooks (2024), pp. 1-26
Closed Access | Times Cited: 1
Post-Stroke Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Attenuates Chronic Changes in Brain Metabolism, Increases Neurotransmitter Levels, and Improves Recovery
Thuy‐Vi V. Nguyen, Rachel H. Crumpacker, Kylie Calderon, et al.
Journal of Pharmacology and Experimental Therapeutics (2021) Vol. 380, Iss. 2, pp. 126-141
Open Access | Times Cited: 10
The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Qiao Wang, Huizhi Wang, Wenjia Meng, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 3
Machine learning‐based radiomics in neurodegenerative and cerebrovascular disease
Meilong Shi, Feng Xiong, He Zhi, et al.
MedComm (2024) Vol. 5, Iss. 11
Open Access
Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease
Danielle A. Simmons, N. Freiberg Alexander, Gloria Cao, et al.
Neurotherapeutics (2024), pp. e00495-e00495
Open Access
Alterations of fractional anisotropy throughout cortico-basal ganglia gray matter in a macaque model of Huntington’s Disease
Alison R. Weiss, William A. Liguore, Kristin Brandon, et al.
Current Research in Neurobiology (2023) Vol. 4, pp. 100090-100090
Open Access | Times Cited: 1
Clinical Correlates Identify ProBDNF and Thrombo-Inflammatory Markers as Key Predictors of Circulating p75NTR Extracellular Domain Levels in Older Adults
Samuel Fleury, Mireille E. Schnitzer, Lawrence Ledoux-Hutchinson, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 1
Ex vivo 100 μm isotropic diffusion MRI‐based tractography of connectivity changes in the end‐stage R6/2 mouse model of Huntington's disease
Ashwinee Manivannan, Lesley M. Foley, T. Kevin Hitchens, et al.
Neuroprotection/Neuroprotection (Chichester, England. Print) (2022) Vol. 1, Iss. 1, pp. 5-22
Open Access | Times Cited: 1
The Effectiveness of Normalising Neurotrophic Signaling as Treatment Strategies for Huntington’s Disease
Zita Man Wai Ng
Journal of Student Research (2022) Vol. 11, Iss. 4
Open Access
Post-stroke administration of the p75 neurotrophin receptor modulator, LM11A-31, attenuates chronic changes in brain metabolism, increases neurotransmitter levels, and improves recovery
Thuy‐Vi V. Nguyen, Rachel H. Crumpacker, Kylie Calderon, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access
Page 1

Scroll to top